Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Banco Santander SA — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Banco Santander SA trades at $14.79 (market cap $211.88B). The key difference: Banco Santander SA is far larger — about 22.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Banco Santander SA pays a 1.89% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | SAN | |
|---|---|---|
Market Cap | $9.39B | $211.88B |
Sector | Health | Financials |
52-Week High | $356.25 | $14.71 |
52-Week Low | $241.71 | $9.37 |
Enterprise Value | $9.14B | — |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Banco Santander (SAN) trades at $14.70, up 0.34% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with a P/E of 14.39, net income margin of 26.25% for 2026, and record profits in H1 2026. Recent news highlights Federal Reserve approval for its $12 billion Webster Bank acquisition, expected to close August 20, 2026, and its rise as Spain's most valuable company.
Outlook is positive given analyst consensus (64% buy ratings), solid profitability, and strategic acquisitions, but risks include regulatory scrutiny in Spain, volatile cash flows, and earnings misses in two of the last three quarters. The stock offers value with growth potential amid integration execution and macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
